Cargando…

In vitro comparison of the adsorption of inflammatory mediators by blood purification devices

BACKGROUND: Septic shock, a leading cause of acute kidney injury, induces release of pro-/anti-inflammatory mediators, leading to increased mortality and poor renal recovery. This is the first in vitro study directly comparing three single-use blood purification devices in terms of removing sepsis-a...

Descripción completa

Detalles Bibliográficos
Autores principales: Malard, Benjamin, Lambert, Corine, Kellum, John A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935601/
https://www.ncbi.nlm.nih.gov/pubmed/29728790
http://dx.doi.org/10.1186/s40635-018-0177-2
_version_ 1783320298167205888
author Malard, Benjamin
Lambert, Corine
Kellum, John A.
author_facet Malard, Benjamin
Lambert, Corine
Kellum, John A.
author_sort Malard, Benjamin
collection PubMed
description BACKGROUND: Septic shock, a leading cause of acute kidney injury, induces release of pro-/anti-inflammatory mediators, leading to increased mortality and poor renal recovery. This is the first in vitro study directly comparing three single-use blood purification devices in terms of removing sepsis-associated mediators and endotoxins. METHODS: In vitro hemoperfusion was performed using oXiris(®), CytoSorb(®), and Toraymyxin(®). Heparinized human plasma from healthy volunteers was pre-incubated with pathologic quantities of inflammatory mediators and filtered in a closed-loop circulation model for 2 h. For each device, the removal of 27 inflammatory mediators was measured over time. Endotoxin removal mediated by oXiris and Toraymyxin was assessed using hemoperfusion over 6 h. RESULTS: Endotoxin (lipopolysaccharide) removal was most rapid with Toraymyxin; mean adsorptive clearance over the first 30 min was ~ 20 ml/min vs ~ 8 ml/min with oXiris (p < 0.05). There was minimal endotoxin removal with CytoSorb (1 ml/min). At 120 min, there was no significant difference between the endotoxin removal rates using oXiris (mean ± standard deviation, 68.0 ± 4.4%) and Toraymyxin (83.4 ± 3.8%); both were significantly higher vs CytoSorb (− 6.3 ± 4.9%; p < 0.05). Total removal with oXiris was 6.9 μg vs 9.7 μg for Toraymyxin, where the total lipopolysaccharide quantity introduced was approximately 15.8 μg. Removal rates of pro-/anti-inflammatory cytokines and other inflammatory mediators were similar between oXiris and CytoSorb and were higher with CytoSorb and oXiris vs Toraymyxin. Granulocyte colony-stimulating factor was only effectively adsorbed by CytoSorb (99.4%). Differences were detected between the adsorption mechanism of the devices; binding to oXiris was mainly ionic, while CytoSorb was hydrophobic. No specific protein adsorption was found qualitatively with Toraymyxin. CONCLUSIONS: Adsorption rate kinetics varied for individual inflammatory mediators using the three blood purification devices. Mechanisms of adsorption differed between the devices. oXiris was the only device tested that showed both endotoxin and cytokine removal. oXiris showed similar endotoxin adsorption to Toraymyxin and similar adsorption to CytoSorb for the removal of other inflammatory mediators. Differences in device removal capacities could enable treatment to be more tailored to patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40635-018-0177-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5935601
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-59356012018-05-09 In vitro comparison of the adsorption of inflammatory mediators by blood purification devices Malard, Benjamin Lambert, Corine Kellum, John A. Intensive Care Med Exp Research BACKGROUND: Septic shock, a leading cause of acute kidney injury, induces release of pro-/anti-inflammatory mediators, leading to increased mortality and poor renal recovery. This is the first in vitro study directly comparing three single-use blood purification devices in terms of removing sepsis-associated mediators and endotoxins. METHODS: In vitro hemoperfusion was performed using oXiris(®), CytoSorb(®), and Toraymyxin(®). Heparinized human plasma from healthy volunteers was pre-incubated with pathologic quantities of inflammatory mediators and filtered in a closed-loop circulation model for 2 h. For each device, the removal of 27 inflammatory mediators was measured over time. Endotoxin removal mediated by oXiris and Toraymyxin was assessed using hemoperfusion over 6 h. RESULTS: Endotoxin (lipopolysaccharide) removal was most rapid with Toraymyxin; mean adsorptive clearance over the first 30 min was ~ 20 ml/min vs ~ 8 ml/min with oXiris (p < 0.05). There was minimal endotoxin removal with CytoSorb (1 ml/min). At 120 min, there was no significant difference between the endotoxin removal rates using oXiris (mean ± standard deviation, 68.0 ± 4.4%) and Toraymyxin (83.4 ± 3.8%); both were significantly higher vs CytoSorb (− 6.3 ± 4.9%; p < 0.05). Total removal with oXiris was 6.9 μg vs 9.7 μg for Toraymyxin, where the total lipopolysaccharide quantity introduced was approximately 15.8 μg. Removal rates of pro-/anti-inflammatory cytokines and other inflammatory mediators were similar between oXiris and CytoSorb and were higher with CytoSorb and oXiris vs Toraymyxin. Granulocyte colony-stimulating factor was only effectively adsorbed by CytoSorb (99.4%). Differences were detected between the adsorption mechanism of the devices; binding to oXiris was mainly ionic, while CytoSorb was hydrophobic. No specific protein adsorption was found qualitatively with Toraymyxin. CONCLUSIONS: Adsorption rate kinetics varied for individual inflammatory mediators using the three blood purification devices. Mechanisms of adsorption differed between the devices. oXiris was the only device tested that showed both endotoxin and cytokine removal. oXiris showed similar endotoxin adsorption to Toraymyxin and similar adsorption to CytoSorb for the removal of other inflammatory mediators. Differences in device removal capacities could enable treatment to be more tailored to patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40635-018-0177-2) contains supplementary material, which is available to authorized users. Springer International Publishing 2018-05-04 /pmc/articles/PMC5935601/ /pubmed/29728790 http://dx.doi.org/10.1186/s40635-018-0177-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research
Malard, Benjamin
Lambert, Corine
Kellum, John A.
In vitro comparison of the adsorption of inflammatory mediators by blood purification devices
title In vitro comparison of the adsorption of inflammatory mediators by blood purification devices
title_full In vitro comparison of the adsorption of inflammatory mediators by blood purification devices
title_fullStr In vitro comparison of the adsorption of inflammatory mediators by blood purification devices
title_full_unstemmed In vitro comparison of the adsorption of inflammatory mediators by blood purification devices
title_short In vitro comparison of the adsorption of inflammatory mediators by blood purification devices
title_sort in vitro comparison of the adsorption of inflammatory mediators by blood purification devices
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935601/
https://www.ncbi.nlm.nih.gov/pubmed/29728790
http://dx.doi.org/10.1186/s40635-018-0177-2
work_keys_str_mv AT malardbenjamin invitrocomparisonoftheadsorptionofinflammatorymediatorsbybloodpurificationdevices
AT lambertcorine invitrocomparisonoftheadsorptionofinflammatorymediatorsbybloodpurificationdevices
AT kellumjohna invitrocomparisonoftheadsorptionofinflammatorymediatorsbybloodpurificationdevices